M a i n r e s u l t s
In general, the quality of the studies was poor, with few studies reporting blinding.
The pooled DOR for the accuracy of MRI for diagnosis of MS was 9 (95% CI 5 to 16) in cohort studies. Studies of other designs provided much higher estimates of the diagnostic accuracy (pooled DOR 213, CI 85 to 535). The reference standard was clinical follow-up alone in most studies, with mean duration of follow-up in the cohort studies ranging from 7 months to 14 years (median 3 y). Only 2 studies followed patients for ≥ 10 years (Table) . Studies with longer followup had higher specificity but lower sensitivity. Various criteria were used for the MRI diagnosis of MS. 3 studies using the McDonald 2001 criteria, which combine MRI with clinical information, showed better test characteristics (+LR range 2.7 to 8.7 and −LR range 0.1 to 0.5) than 6 studies using the Paty, Barkhof, or Fazekas criteria, which are based on MRI alone (+LR range 1.6 to 3.6 and -LR range 0.2 to 0.7).
C o n c l u s i o n
Magnetic resonance imaging on its own has limited usefulness for ruling in or ruling out multiple sclerosis. 
C o m m e n t a r y
Whiting and colleagues concluded that the diagnostic accuracy of MRI alone is insufficient for it to be useful in ruling in or ruling out a diagnosis of MS. The reference standard considered in most of the included studies, a second clinical episode, is not a gold standard. The gold standard is the pathological confirmation of demyelinating disease. However, biopsy and autopsy data are rarely available. Vague recurring sensory symptoms and "soft" findings on examination, which may be taken as "evidence" for dissemination in time and space, are no more, and may be less, reliable than MRI abnormalities. The accuracy of clinical diagnosis was not addressed in this review. Many of the included studies addressed the usefulness of MRI in "clinically isolated syndromes," such as optic neuritis, that may herald MS. "Conversion" to definite MS may occur at follow-up intervals longer than those considered by most studies in the review (1) . The pretest probability of MS for patients who present with such typical demyelinating syndromes as optic neuritis and partial transverse myelitis is very high. It is hard to substantively augment the probability of "conversion" to MS in these patients with any diagnostic test.
Restricting the review to studies that involved patients presenting with syndromes with a broad differential diagnosis that includes MS, who have a lower pretest probability than those with the classical "clinically isolated syndromes," might better address the value of MRI in MS diagnosis. Distinguishing the "punched-out" corpus callosum lesions of retinocochlear vasculopathy (the Susac syndrome) from the flame-shaped ovoid lesions of MS (2) or recognizing the typical temporal pole T2 lesions of CADASIL (3) is enormously helpful when seeing patients for whom the diagnosis of MS is reasonably considered but erroneous. The value of MRI in monitoring disease activity and in guiding the implementation of disease-modifying therapy should also be considered.
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